Kinetic modelling of the role of the aldehyde dehydrogenase enzyme and the breast cancer resistance protein in drug resistance and transport

被引:1
|
作者
Atari, M. I. [1 ]
Chappell, M. J. [1 ]
Errington, R. J. [2 ]
Smith, P. J. [3 ]
Evans, N. D. [1 ]
机构
[1] Univ Warwick, Sch Engn, Coventry CV4 7AL, W Midlands, England
[2] Cardiff Univ, Univ Wales, Coll Med, Dept Med Biochem & Immunol, Cardiff CF14 4XN, S Glam, Wales
[3] Cardiff Univ, Univ Wales, Coll Med, Dept Pathol, Cardiff CF14 4XN, S Glam, Wales
基金
英国生物技术与生命科学研究理事会;
关键词
Efflux pump; Drug kinetics; Topotecan; Aldehyde dehydrogenase; Structural identifiability; Parameter estimation; DNA TOPOISOMERASE-I; MULTIDRUG-RESISTANCE; STEADY-STATE; TOPOTECAN; CELLS; IDENTIFIABILITY; CAMPTOTHECINS; BCRP/ABCG2; ABCG2;
D O I
10.1016/j.cmpb.2010.06.008
中图分类号
TP39 [计算机的应用];
学科分类号
081203 ; 0835 ;
摘要
A compartmental model for the in vitro uptake kinetics of the anti-cancer agent topotecan (TPT) has been extended from a previously published model. The extended model describes the drug activity and delivery of the pharmacologically active form to the DNA target as well as the catalysis of the aldehyde dehydrogenase (ALDH) enzyme and the elimination of drug from the cytoplasm via the efflux pump. Verification of the proposed model is achieved using scanning-laser microscopy data from live human breast cancer cells. Before estimating the unknown model parameters from the experimental in vitro data it is essential to determine parameter uniqueness (or otherwise) from this imposed output structure. This is formally performed as a structural identifiability analysis, which demonstrates that all of the unknown model parameters are uniquely determined by the output structure corresponding to the experiment. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:93 / 103
页数:11
相关论文
共 50 条
  • [21] Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein
    Juvale, Kapil
    Pape, Veronika F. S.
    Wiese, Michael
    BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (01) : 346 - 355
  • [22] The role of microvesicles in cancer progression and drug resistance
    Jorfi, Samireh
    Inal, Jameel M.
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2013, 41 : 293 - 298
  • [23] Role of Breast Cancer Resistance Protein in the Adaptive Response to Cholestasis
    Mennone, Albert
    Soroka, Carol J.
    Harry, Kathy M.
    Boyer, James L.
    DRUG METABOLISM AND DISPOSITION, 2010, 38 (10) : 1673 - 1678
  • [24] Expression of Multidrug Resistance 1, Lung Resistance Protein and Breast Cancer Resistance Protein Genes in Chronic Leukemias
    Iseri, Ozlem D.
    Kars, Meltem D.
    Mutlu, Pelin
    Avcu, Ferit
    Ural, Ali U.
    Gunduz, Ufuk
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2011, 21 (02): : 92 - 100
  • [25] Breast cancer resistance protein-mediated topotecan resistance in ovarian cancer cells
    Jia, P
    Wu, S
    Li, F
    Xu, Q
    Wu, M
    Chen, G
    Liao, G
    Wang, S
    Zhou, J
    Lu, Y
    Ma, D
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (06) : 1042 - 1048
  • [26] Paclitaxel in breast cancer - drug resistance and strategies to counteract it
    Zajdel, Alicja
    Wolny, Daniel
    Kalucka-Janik, Magdalena
    Wilczok, Adam
    POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ, 2019, 73 : 508 - 515
  • [27] Nanomaterials: breaking the bottleneck of breast cancer drug resistance
    Guan, Chao
    Han, Yahao
    Ling, Zhenzheng
    Meng, Xiang
    Zhang, Baolin
    Dong, Wanwei
    Zhang, Di
    Chen, Keyan
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [28] Transport of Diclofenac by Breast Cancer Resistance Protein (ABCG2) and Stimulation of Multidrug Resistance Protein 2 (ABCC2)-Mediated Drug Transport by Diclofenac and Benzbromarone
    Lagas, Jurjen S.
    van der Kruijssen, Cornelia M. M.
    van de Wetering, Koen
    Beijnen, Jos H.
    Schinkel, Alfred H.
    DRUG METABOLISM AND DISPOSITION, 2009, 37 (01) : 129 - 136
  • [29] Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer
    Mehendale-Munj, Sonali
    Sawant, Shivangi
    CURRENT DRUG TARGETS, 2021, 22 (04) : 409 - 417
  • [30] The Role of Non-Coding RNAs in Breast Cancer Drug Resistance
    Tian, Jin-hai
    Liu, Shi-hai
    Yu, Chuan-yang
    Wu, Li-gang
    Wang, Li-bin
    FRONTIERS IN ONCOLOGY, 2021, 11